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ABSTRACT
Objective Peroxisome proliferator-activated receptor α
(PPARα) is a nuclear receptor expressed in tissues with
high oxidative activity that plays a central role in
metabolism. In this work, we investigated the effect of
hepatocyte PPARα on non-alcoholic fatty liver disease
(NAFLD).
Design We constructed a novel hepatocyte-speciﬁc
PPARα knockout (Pparαhep−/−) mouse model. Using this
novel model, we performed transcriptomic analysis
following fenoﬁbrate treatment. Next, we investigated
which physiological challenges impact on PPARα.
Moreover, we measured the contribution of hepatocytic
PPARα activity to whole-body metabolism and ﬁbroblast
growth factor 21 production during fasting. Finally, we
determined the inﬂuence of hepatocyte-speciﬁc PPARα
deﬁciency in different models of steatosis and during
ageing.
Results Hepatocyte PPARα deletion impaired fatty acid
catabolism, resulting in hepatic lipid accumulation during
fasting and in two preclinical models of steatosis. Fasting
mice showed acute PPARα-dependent hepatocyte activity
during early night, with correspondingly increased
circulating free fatty acids, which could be further
stimulated by adipocyte lipolysis. Fasting led to mild
hypoglycaemia and hypothermia in Pparαhep−/− mice
when compared with Pparα−/− mice implying a role of
PPARα activity in non-hepatic tissues. In agreement with
this observation, Pparα−/− mice became overweight
during ageing while Pparαhep−/− remained lean.
However, like Pparα−/− mice, Pparαhep−/− fed a
standard diet developed hepatic steatosis in ageing.
Conclusions Altogether, these ﬁndings underscore the
potential of hepatocyte PPARα as a drug target for
NAFLD.
INTRODUCTION
Precise control of fatty acid metabolism is essential.
Defective fatty acid homeostasis regulation may
induce lipotoxic tissue damage, including hepatic
steatosis.1 Peroxisome proliferator-activated recep-
tors (PPARs) are transcription factors that serve as
fatty acid receptors and help regulate gene expres-
sion in response to fatty acid-derived stimuli.2
PPARs act as ligand-activated receptors, controlling
target gene transcription. The three PPAR isotypes,
PPARα, PPARβ/δ and PPARγ, display speciﬁc tissue
expression patterns and control different biological
functions,3 but all bind lipids and control lipid
homeostasis in different tissues, including the liver.2
A healthy liver does not accumulate lipids, but it
plays central roles in fatty acid anabolism and
export to peripheral organs, including white
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Signiﬁcance of this study
What is already known on this subject?
▸ Peroxisome proliferator-activated receptor α
(PPARα) is a nuclear receptor expressed in
many tissues and is responsible for several
important metabolic controls, especially during
fasting.
▸ PPARα is a target for the hypolipidemic drugs
of the ﬁbrate family.
▸ PPARα is less expressed in the liver of patients
with non-alcoholic fatty liver diseases (NAFLD).
▸ Several PPAR-targeting molecules, including
dual agonists, are currently under investigation
for NAFLD treatment.
What are the new ﬁndings?
▸ Hepatocyte-restricted PPARα deletion impairs
liver and whole-body fatty acid homeostasis.
▸ Hepatic PPARα responds to acute and chronic
adipose tissue lipolysis.
▸ Hepatic PPARα regulates circadian ﬁbroblast
growth factor 21 (FGF21) and fasting-induced
FGF21, and is partially responsible for the
FGF21 increase in steatohepatitis.
▸ Hepatocyte-restricted PPARα deletion is
sufﬁcient to promote NAFLD and
hypercholesterolaemia during ageing, but does
not lead mice to become overweight.
How might it impact on clinical practice in
the foreseeable future?
▸ This work emphasises the relevance and
potential of hepatic PPARα as a drug target for
NAFLD.
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adipose tissue for energy storage.4 During dietary restriction,
hepatic fatty acid catabolism is also critical for using free fatty
acids (FFAs) released from white adipose tissues. PPARα is the
most abundant isotype in hepatocytes and is involved in many
aspects of lipid metabolism,5 6 including fatty acid degradation,
synthesis, transport, storage, lipoprotein metabolism and keto-
genesis during fasting.7–9 In addition, PPARα controls glycerol
use for gluconeogenesis9 as well as autophagy10 in response to
fasting. Moreover, PPARα regulates the expression of the ﬁbro-
blast growth factor 21 (FGF21) during starvation.11 12 In turn,
FGF21 acts as an endocrine hormone targeting various func-
tions including metabolic control.13 Finally, PPARα helps
repress the acute-phase response and inﬂammation in the
liver.14
Obesity can lead to organ and vascular complications.15
Non-alcoholic fatty liver disease (NAFLD), which are consid-
ered the hepatic manifestation of metabolic syndrome, range
from benign steatosis to severe non-alcoholic steatohepatitis
(NASH), potentially further damaging organs.16 Sustained ele-
vation of neutral lipid accumulation (mostly triglycerides in hep-
atocyte lipid droplets) initiates early pathological stages.
Different fatty acid sources contribute to fatty liver develop-
ment, including dietary lipid intake, de novo lipogenesis and
adipose tissue lipolysis.4 In NAFLD, 60% of fatty acids accumu-
lated in steatotic liver are adipose-derived.17
Preclinical18–21 and clinical22 studies highlight that PPARα
inﬂuences NAFLD and NASH. Mice lacking PPARα develop
steatosis during fasting,7 8 suggesting the importance of PPARα
activity for using FFA released from adipocytes. However,
PPARα is expressed and active in many tissues, including skeletal
muscles,23 adipose tissues,24 25 intestines,26 kidneys27 and
heart,28 which all contribute to fatty acid homeostasis.
Therefore, it remains unknown whether the increased steatosis
susceptibility in mice lacking PPARα depends on PPARα activity
only in hepatocytes or also in other organs.
Here we investigated consequences of hepatocyte-speciﬁc
Pparα deletion, focusing on effects on fatty acid metabolism in
NAFLD, ranging from steatosis to steatohepatitis. We report the
ﬁrst evidence that adipocyte lipolysis correlates with and stimu-
lates NAFLD when hepatocytes are lacking PPARα. Our data
establish that hepatocyte-restricted Pparα deletion is sufﬁcient to
promote steatosis, emphasising this receptor’s relevance as a
drug target in NAFLD.
MATERIALS AND METHODS
Animals
Generation of ﬂoxed-Pparα mice and of Pparα hepatocyte-
speciﬁc knockout (Pparαhep−/−) animals is described in online
supplementary ﬁle 1.
In vivo experiments
In vivo studies followed the European Union guidelines for
laboratory animal use and care, and were approved by an inde-
pendent ethics committee.
Detailed experimental protocols are provided in online sup-
plementary ﬁle 1.
Plasma analysis
Plasma FGF21 and insulin, respectively, were assayed using the
rat/mouse FGF21 ELISA kit (EMD Millipore) and the ultrasen-
sitive mouse insulin ELISA kit (Crystal Chem) following the
manufacturer’s instructions. Aspartate transaminase, alanine
transaminase (ALT), total cholesterol, LDL cholesterol and HDL
cholesterol were determined using a COBAS-MIRA+ biochem-
ical analyser (Anexplo facility).
Circulating glucose and ketone bodies
Blood glucose was measured using an Accu-Chek Go gluc-
ometer (Roche Diagnostics). β-Hydroxybutyrate content was
measured using Optium β-ketone test strips with Optium Xceed
sensors (Abbott Diabetes Care).
Histology
Paraformaldehyde-ﬁxed, parafﬁn-embedded liver tissue was
sliced into 5 μm sections and H&E stained. Visualisation was
performed using a Leica DFC300 camera.
Liver lipids analysis
Detailed experimental protocols are provided in online supple-
mentary ﬁle 1.
Gene expression studies
Total RNA was extracted with TRIzol reagent (Invitrogen).
Transcriptomic proﬁles were obtained using Agilent Whole
Mouse Genome microarrays (4×44k). Microarray data and
experimental details are available in the Gene Expression
Omnibus (GEO) database (accession number GSE73298 and
GSE73299). For real-time quantitative PCR (qPCR), 2 mg RNA
samples were reverse-transcribed using the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems). Online
supplementary ﬁle 2 presents the SYBR Green assay primers.
Ampliﬁcations were performed using an ABI Prism 7300
Real-Time PCR System (Applied Biosystems). qPCR data were
normalised to TATA-box-binding protein mRNA levels, and ana-
lysed with LinRegPCR.v2015.3.
Transcriptomic data analysis
Data were analysed using R (http://www.r-project.org).
Microarray data were processed using Bioconductor packages
(http://www.bioconductor.org, v 2.12)29 as described in GEO
entry GSE26728. Further details are provided in online supple-
mentary ﬁle 1.
Statistical analysis
Data were analysed using R (http://www.r-project.org).
Microarray data were processed using bioconductor packages
(http://www.bioconductor.org) as described in GEO entry
GSE38083. Genes with a q value of <0.001 were considered
differentially expressed between genotypes. Gene Ontology
(GO) Biological Process enrichment was evaluated using condi-
tional hypergeometric tests (GOstats package). For non-
microarray data, differential effects were analysed by analysis of
variance followed by Student’s t-tests with a pooled variance
estimate. A p value <0.05 was considered signiﬁcant.
RESULTS
Generation of hepatocyte-speciﬁc PPARα knockout mice
Progeny carrying the Pparαﬂox/ﬂox alleles (ﬁgure 1A), referred to
as ﬂoxed, were backcrossed in the C57Bl/6J background, and
then crossed with albumin-Cre mice in the same genetic back-
ground, generating a hepatocyte-speciﬁc PPARα knockout
(Pparαﬂox/ﬂoxalbumin-Cre+/−) referred to as Pparαhep−/−
(ﬁgure 1B). PPARα mRNA was not detected in livers from
Pparαhep−/− mice when compared with ﬂoxed and C57Bl6/J
mice (ﬁgure 1C), suggesting that most hepatic PPARα expression
is from hepatocytes. PPARα absence in hepatocytes did not alter
mRNA expression of other PPAR isotypes (ﬁgure 1C).
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Hepatocyte-autonomous effect of fenoﬁbrate on PPARα
activity
To determine whether PPARα response was
hepatocyte-autonomous, we challenged wild-type (WT), ﬂoxed
Pparαhep+/+, Pparα−/− and Pparαhep−/− mice with the PPARα
agonist fenoﬁbrate. We measured mRNA expressions of PPARα
target genes, including Cyp4a10 (ﬁgure 2A) and Cyp4a14
(ﬁgure 2B). Their expressions were strongly induced by fenoﬁ-
brate in WT and in ﬂoxed Pparαhep+/+ mice compared with
Pparα−/− and Pparαhep−/− mice. These samples were also used
for pangenomic expression proﬁling through microarray analysis
(ﬁgure 2C). Differentially expressed gene (DEG) analysis was
subjected to hierarchical clustering, highlighting similar expres-
sion proﬁles between WT and ﬂoxed Pparαhep+/+ mice within
fenoﬁbrate-treated or vehicle-treated groups. Whole-body
Pparα−/− and Pparαhep−/− mice were unresponsive to fenoﬁbrate,
suggesting that fenoﬁbrate-induced hepatic changes were mainly
due to autonomous hepatocyte responses, not secondary to
extrahepatic PPARα activation. GO biological function analysis
revealed that fenoﬁbrate upregulated lipid metabolism, and
repressed immune and defence response, metabolic responses,
and glycosylation and glycoprotein metabolism (ﬁgure 2C,
groups 1, 2, 6 and 7). However, untreated Pparα−/− and
Pparαhep−/− mice showed marked differences (ﬁgure 2C, groups
3, 4, 8 and 9). This implies that the absence of extrahepatic
PPARα has a signiﬁcant impact on the liver transcriptional
proﬁle and underscores the relevance of Pparαhep−/− mice to
deﬁne the hepatocyte autonomous role of the receptor in the
control of liver function.
Hepatocyte PPARα activity is context-speciﬁc
The Pparαhep−/− model was used to determine whether PPARα
could drive hepatic regulations both in fasting-induced fatty acid
catabolism as well as fatty acid anabolism during refeeding. The
Figure 1 Characterisation of the
hepatocyte-speciﬁc peroxisome
proliferator-activated receptor α
(PPARα) knockout mouse model. (A)
Schematic of the targeting strategy to
disrupt hepatic Pparα expression. (B)
PCR analysis of Pparα ﬂoxed (Pparαhep
+/+) and Albumin-Cre (Albumin-Cre+/−)
genes from mice that are liver
wild-type (WT), (Pparαhep+/+) or liver
knockout (Pparαhep−/−) for Pparα
using DNA extracted from different
organs. (C) Relative mRNA expression
levels of Pparα, Pparβ/δ and Pparγ
from liver samples of WT, liver WT
(Pparαhep+/+), Pparα liver knockout
(Pparαhep−/−) and Pparα knockout
(Pparα−/−) mice (n=8 mice per group).
Data represent mean±SEM.
***p≤0.005. FA, ﬂoxed allele; Flp,
ﬂippase; FRT, ﬂippase recognition
target; LoxP, locus of X-overP1; nd, not
detected; PparαΔ, Pparα deletion; WT,
the Albumin-Cre−/− allele.
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fasting–refeeding experimental design was validated by measur-
ing glycaemia (ﬁgure 3A) and expression of fatty acid synthase
(Fasn), which encodes the rate-limiting enzyme in lipogenesis
(ﬁgure 3B). Both were low during fasting, intermediary in ad
libitum-fed animals, and high in refed animals. Cyp4a14 (a well-
known PPARα target) expression was low or undetectable in
Pparαhep−/− animals, and strongly upregulated with fasting in
WT mice (ﬁgure 3C).
Next we evaluated the hepatic transcriptome expression
pattern using microarrays. We performed hierarchical clustering
(ﬁgure 3D). Most PPARα-dependent changes were observed in
fasted mouse livers. Venn diagrams were used to show nutri-
tional status-related PPARα-dependent changes (ﬁgure 3E).
Among the signiﬁcant DEGs, 3048 were related to fasting, 390
to ad libitum-fed animals and 156 to refed mice, suggesting
context-speciﬁc PPARα activity. The results further highlighted
Figure 2 Pharmacological peroxisome proliferator-activated receptor α (PPARα) activation using fenoﬁbrate reveals hepatocyte-speciﬁc
PPARα-dependent biological functions. Liver samples from wild-type (WT), PPARα knockout (Pparα−/−), liver WT (Pparαhep+/+) and Pparα
hepatocyte knockout (Pparαhep−/−) mice treated with fenoﬁbrate (Feno, +) or vehicle (−) by oral gavage for 14 days were collected. (A and B) The
relative gene expression of two speciﬁc PPARα target genes Cyp4a10 (A) and Cyp4a14 (B) was measured by qRT-PCR. Data represent mean±SEM.
**p≤0.01, ***p≤0.005. (C) Heat map representing data from a microarray experiment performed with liver samples. Hierarchical clustering is also
shown, which allows the deﬁnition of nine gene clusters. Gene Ontology (GO) analysis of each cluster revealed signiﬁcant biological functions
(p≤0.05). nd, not detected.
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that fasting, rather than feeding or refeeding, triggered the
broader PPARα-dependent hepatocytic response, with most
upregulated genes related to metabolism (ﬁgure 3E). However,
the expression of several genes was identiﬁed as PPARα depend-
ent regardless of the nutritional condition tested (fasting, but
also feeding and refeeding). These genes are mostly downregu-
lated in the absence of PPARα and pathway analysis highlights
their involvement in mitochondrial fatty acid catabolism (see
online supplementary ﬁle 3).
Biological function analyses revealed that both transcriptional
activation and repression were PPARα sensitive (ﬁgure 3E). The
functions of PPARα-sensitive repressions (GO categories up in
Pparαhep−/− mice) varied with context, and included GO cat-
egories not directly related to metabolism, including acute-phase
Figure 3 Hepatocyte-speciﬁc peroxisome proliferator-activated receptor α (PPARα) function is dependent on nutritional status. Wild-type (WT) and
PPARα liver knockout (Pparαhep−/−) male 8-week-old mice were fed ad libitum, fasted for 24 h, or fasted for 24 h and refed for 24 h. All mice were
killed at ZT14, and sera and livers were collected. (A) Quantiﬁcation of circulating glucose levels. (B, C) Relative mRNA expressions of Fasn (B) and
Cyp4a14 (C) in liver samples quantiﬁed by qRT-PCR. Data represent mean±SEM. *p≤0.05, **p≤0.01, ***p≤0.005. (D) Heat map was performed
based on average gene expression levels from WT (n=12 (6 WT and 6 Pparαhep+/+)) and from Pparαhep−/− (n=6). (E) Venn diagram and associated
Gene Ontology (GO) function analysis (p≤0.05), GO categories corresponding to functions down in the absence of PPARα are in bold, GO
categories corresponding to functions up in the absence of PPARα are in regular font.
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response (fed), translation (refed) and protein glycosylation
(fasted).
Hepatocyte PPARα is required for liver and whole-body
fatty acid homeostasis in fasting
We next used Pparαhep−/− mice to determine the contribution of
hepatocyte PPARα, and compared it with Pparα−/− and WT
mice. We measured FFA and β-hydroxybutyrate (ketonaemia)
levels in fasted and non-fasted mice (ﬁgure 4A). Plasma FFA was
elevated in fasting mice of all three genotypes, but was signiﬁ-
cantly higher in Pparαhep−/− and Pparα−/− mice compared with
controls. Fasting strongly increased ketone body levels in WT
mice and to a lesser degree in Pparαhep−/− and Pparα−/− mice.
This suggests that hepatic PPARα is required for FFA disposal
and for β-hydroxybutyrate production. Correspondingly, fasting
Pparαhep−/− and Pparα−/− mice showed elevated hepatic trigly-
cerides and cholesterol esters (ﬁgure 4B), and substantial centri-
lobular steatosis (ﬁgure 4C), conﬁrming that hepatic PPARα
expression is required for fasting-induced FFA catabolism.
PPARα absence led to defective expressions of PPARα target
genes (ﬁgure 4D), including those involved in fatty acid catabol-
ism and processing in lipid droplets (ﬁgure 4E). As a conse-
quence of PPARα deﬁciency in hepatocytes, Pparαhep−/− mice
exhibit a distinct fasting-induced fatty acid proﬁle with a signiﬁ-
cant increase in oleic acid (C18:1n–9) and linoleic acid
(C18:2n–6) when compared with WT mice (see online supple-
mentary ﬁle 4).
Hepatocyte-speciﬁc Pparα deletion impairs constitutive and
fasting-induced FGF21 expression
FGF21 is a hepatokine mainly produced by the liver. We exam-
ined liver Fgf21 mRNA expression (ﬁgure 5A) and plasma
FGF21 levels (ﬁgure 5B) in fed and fasted animals. We identi-
ﬁed a constitutive expression peak during the day (ZT8) in both
groups, and a fasting-triggered night-time peak (ZT16). In
Pparαhep−/− mice, we examined whether fasting-induced FGF21
expression/production was strictly dependent on PPARα hepatic
activity. Pparα−/− and Pparαhep−/− mice showed very low plasma
FGF21 protein at ZT8 or at ZT16 with fasting (ﬁgure 5C).
Since FGF21 has been shown to reduce steatosis and lipotoxic
lipids13 30 we questioned whether the absence of FGF21 deter-
mines fasting-induced steatosis observed in Pparαhep−/− and
Pparα−/− mice. FGF21 expression was rescued by adenoviral
delivery both in Pparαhep−/− and in Pparα−/− mice (ﬁgure 5D).
Comparable expression of FGF21 (ﬁgure 5E) was obtained in
liver of WT, Pparαhep−/− and in Pparα−/− mice. FGF21-sensitive
genes such as G6pd and Scd1 showed signiﬁcantly different
expression in response to FGF21 overexpression (ﬁgure 5E).
However, FGF21 only reduced hepatic triglycerides and choles-
terol esters in WT mice, but not in Pparαhep−/− and in Pparα−/−
mice (ﬁgure 5F, G). These results indicate that the
fasting-induced steatosis occurring in Pparαhep−/− and in Pparα−/
− mice does not depend on the lack of FGF21. This is in line
with our observations that FGF21- and PPARα-sensitive target
genes are different (see online supplementary ﬁle 5A).
Moreover, it is also consistent with the observation that FGF21
overexpression does not rescue the expression of PPARα target
genes and conversely that PPARα-sensitive regulations occur in
Fgf21−/− mice (see online supplementary ﬁle 5B, C).
In addition to their defective fatty acid catabolism, Pparα−/−
mice are hypoglycaemic and hypothermic during fasting.7
Because FGF21 is important for glucose homeostasis and for
thermogenesis,13 we investigated the role of hepatocyte PPARα
in controlling fasting glycaemia and body temperature. Both
Pparαhep−/− and Pparα−/− mice were hypoglycaemic and hypo-
thermic compared with WT mice during fasting. However, this
phenotype was much stronger in fasted Pparα−/− mice compared
with fasted Pparαhep−/− mice (ﬁgure 5H-J), indicating that extra-
hepatic PPARα strongly inﬂuenced whole-body glucose homeo-
stasis and temperature independent of hepatocytic PPARα
activity and FGF21 production.
Fasting-enhanced hepatocytic PPARα activity is
time-restricted and sensitive to adipocyte lipolysis
We next tested the kinetics of other fasting-induced hepatic
PPARα activity in vivo. We used several measures of PPARα
activity, including Fgf21 (ﬁgure 5A) and Vanin1, Cyp4a10,
Cyp4a14 and Fsp27 mRNAs (ﬁgure 6A), since these genes were
most sensitive to fasting and to fenoﬁbrate, and were strictly
PPARα dependent (see online supplementary ﬁles 6–10A).
Plasma FFA and glucose levels were also measured during
fasting (ﬁgure 6B). FFA were markedly increased in the early
night (ZT14–ZT16). The FFA pattern was correlated with the
PPARα mRNA expression proﬁle and expressions of Fgf21,
Vanin1, Cyp4a10, Cyp4a14 and Fsp27 (ﬁgures 5A and 6A).
This strongly suggested that FFA released from adipocytes
during fasting-inﬂuenced hepatic PPARα expression and activity
without inﬂammatory response since hepatic Tnfα mRNA
expression was not sensitive to fasting. We further determined
that acute treatment of fasted mice with the β3-adrenergic
receptor agonist CL316243 enhanced circulating FFA levels in
WTand Pparαhep−/− mice (ﬁgure 6C), and increased expressions
of Fgf21, Cyp4a14, Vanin1, Cyp4a10 and Fsp27 in WT mice
but not Pparαhep−/− mice (ﬁgure 6D) without inducing Tnf α in
response to fasting or in response to CL316243 (see online sup-
plementary ﬁle 10C and D). These data support a role for acute
adipocyte lipolysis as a signal for hepatocyte PPARα activity
during fasting.
Hepatocyte PPARα is required for protection in
steatohepatitis
We next examined whether the hepatocytic PPARα response to
chronic lipolysis occurred during methionine-deﬁcient and
choline-deﬁcient diet (MCD)-induced weight loss. In rodents,
this diet rapidly promotes lipolysis in adipocytes, resulting in
steatohepatitis. On the MCD diet, mice of each genotype
showed weight loss (ﬁgure 7A), steatosis (ﬁgure 7B), and
increased hepatic triglycerides, cholesterol esters (ﬁgure 7C) and
plasma ALT (ﬁgure 7D). Compared with WT, Pparαhep−/− and
Pparα−/− mice showed greater steatosis and liver damage, sug-
gesting a more severe MCD diet-induced phenotype without
hepatocyte PPARα. MCD also induced increased expressions of
Cyp4a14 and Vanin1 in WT mice, but not Pparαhep−/− or
Pparα−/− mice (ﬁgure 7E). Fgf21 mRNA (ﬁgure 7E) and circu-
lating FGF21 (ﬁgure 7F) were increased through a mechanism
that is partly dependent on hepatic PPARα. Overall, hepatocyte-
speciﬁc Pparα deletion aggravated MCD diet-induced liver
damage, correlating with defective PPARα-dependent pathway
upregulation in response to chronic lipolysis.
Additionally, we questioned whether hepatocyte PPARα may
also be required for the protection of the liver during early hits
in steatosis such as those occurring in response to short-term
exposure to a high-fat diet (HFD). Over 2 weeks of HFD,
mouse liver accumulated hepatic triglycerides and cholesterol
esters. Importantly, this steatosis was twice higher in Pparαhep−/−
mice than in WT mice, and was further elevated in Pparα−/−
mice (see online supplementary ﬁle 11). Altogether, these data
suggest that hepatic PPARα is essential in hepatoprotection.
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Hepatocyte PPARα deﬁciency leads to steatosis and
hypercholesterolaemia but not excess weight gain in ageing
mice
Lastly, we questioned the long-term consequences of
hepatocyte-speciﬁc Pparα deletion during ageing. More speciﬁc-
ally, since PPARα is broadly expressed in metabolic tissues, we
aimed at clarifying whether the steatosis that develops in aged
whole-body Pparα−/− mice is due to the hepatocytic defect in
PPARα activity. WT, Pparαhep−/− and Pparα−/− mice were fed a
standard diet over 1 year. Pparα−/− mice, but not Pparαhep−/−
mice, grew overweight with ageing (ﬁgure 8A–C). Both Pparαhep
−/− and Pparα−/− mice showed spontaneous centrilobular stea-
tosis (ﬁgure 8D), elevated hepatic triglycerides and hepatic chol-
esterol esters (ﬁgure 8E), as well as hypercholesterolaemia (see
ﬁgure 8F online supplementary ﬁle 12) without hyperglycaemia
(ﬁgure 8G). Overall, hepatocyte-speciﬁc PPARα deﬁciency was
sufﬁcient to induce spontaneous steatosis and disrupt whole-
body fatty acid as well as cholesterol homeostasis, but did not
affect weight gain and diabetes during ageing.
DISCUSSION
NAFLD are a spectrum of diseases presenting a major public
health concern that is strongly linked with obesity. Most accu-
mulated hepatic fatty acids in NAFLD come from increased
non-esteriﬁed FFA in the fasting state.17 Thus, it is essential to
deﬁne the mechanisms by which the liver adapts to this inﬂux.
FFA processing largely involves the fatty acid oxidative pathway,
coupled to ketogenesis allowing the liver to use lipids,31 which
is critical during fasting and requires transcriptional regulation
of rate-limiting enzymes.32
Whole-body Pparα−/− mice show impaired coping with pro-
longed fasting, resulting in defective fatty acid oxidation and
steatosis, hypoglycaemia and hypothermia. However, PPARα
also contributes to metabolic homeostasis through expression in
other tissues. Here we investigated the impact of hepatocyte-
speciﬁc PPARα deletion on liver physiology and lipid metabol-
ism in vivo. To our knowledge, this is the ﬁrst report that select-
ive PPARα deletion in hepatocytes (Pparαhep−/−) was sufﬁcient
to promote hepatic steatosis.
PPARα is targeted by several ﬁbrate drugs,33 and by pan-agonists
for PPAR isotypes21 that are currently in clinical trials for NASH
treatment. Using Pparαhep−/− mice, we demonstrated an autono-
mous transcriptional response of hepatocytes to fenoﬁbrate, indi-
cating that ﬁbrates’ effects on the liver gene expression are largely
independent from those in extrahepatic tissues. Moreover, liver
gene expression proﬁles markedly differed between untreated
Pparα−/− and Pparαhep−/− mice, suggesting that extrahepatocytic
PPARα activity substantially inﬂuenced the hepatic transcriptome.
Food restriction induces PPARα activity, and endogenous
PPARα ligand production requires hepatic lipogenesis, which
Figure 4 Fasting is the major inducer of hepatic peroxisome proliferator-activated receptor α (PPARα) activity. Wild-type (WT), hepatocyte-speciﬁc
PPARα knockout (Pparαhep−/−) and total PPARα knockout (Pparα−/−) mice were fed ad libitum or fasted for 24 h and then killed. (A) Quantiﬁcation
of plasma free fatty acids (FFAs) and ketone bodies (ketonaemia). (B) Hepatic triglycerides and cholesterol esters hepatic levels. (C) Representative
pictures of H&E staining of liver sections. Scale bars, 100 mm. (D) Relative mRNA expression levels of Pparα, Cyp4a14 and Vnn1 in liver samples
determined by qRT-PCR. (E) Quantiﬁcation of mRNA expression of Acox1, Hmgcs2, Acadl, Fsp27 and Plin5 by qRT-PCR. Data shown as mean±SEM.
*p≤0.05, **p≤0.01, ***p≤0.005.
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Figure 5 Hepatocyte and extrahepatocyte peroxisome proliferator-activated receptor α (PPARα) regulate ﬁbroblast growth factor 21 (FGF21),
glycaemia and body temperature during fasting. (A and B) Eleven-week-old male mice of the C57Bl/6J background were fed ad libitum or fasted for
24 h, and were killed around the clock from ZT0 to ZT24. (A) Fgf21 mRNA was quantiﬁed by qRT-PCR. (B) Quantiﬁcation of circulating FGF21 levels
by ELISA. (C) Twelve-week-old wild-type (WT), PPARα-hepatocyte knockout (Pparαhep−/−) and PPARα knockout (Pparα−/−) male mice were fed ad
libitum or fasted for 16 h and blood was collected at ZT8 (ZT8 fed) or at ZT16 (ZT16 fasted). FGF21 plasma level was determined by ELISA. (D–G)
Male mice of WT, Pparαhep−/− and Pparα−/− genotypes were infected with an adenoviral construct containing cDNA of Fgf21 or an empty vector.
Mice were sacriﬁced after a 24 h fasting period at ZT14. (D) Quantiﬁcation of circulating FGF21 levels by ELISA. (E) Fgf21, G6pd and Scd1 mRNAs
were quantiﬁed by qRT-PCR. (F) Quantiﬁcation of hepatic cholesterol esters and triglycerides. (G) Representative pictures of H&E staining of liver
sections. Scale bars, 100 mm. (H) Plasma glucose level was monitored over a 24 h fasting period from ZT0 to ZT24 in WT, Pparαhep−/− and Pparα−/−
mice. ( I, J) Plasma glucose (I) and body temperature (J) were determined at ZT0 in fed mice or at ZT0 in mice fasted for 24 h. Data are shown as
mean±SEM. *p≤0.05, **p≤0.01, ***p≤0.005.
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increases upon feeding.34 35 Thus, PPARα may be important
during fasting-induced lipid catabolism and in the response to
anabolic fatty acid-derived signals. Our data revealed the
context dependency of PPARα hepatocytic activity deﬁned by
DEGs. This activity was clearly the highest during fasting.
During fasting, hepatocyte-speciﬁc PPARα deletion resulted in
steatosis, increased plasma FFA and impaired ketone bodies.
This supports the concept that FFA released from adipose stores
during fasting may activate PPARα for hepatic use. Accordingly,
we found that Pparαhep−/− mice accumulate high oleic and
Figure 6 Hepatocyte peroxisome proliferator-activated receptor α (PPARα) activity is induced by adipose tissue lipolysis. (A and B) Liver samples
were collected from male wild-type (WT) C57Bl/6J mice that were fed ad libitum (black curve) or fasted (blue curve) over 24 h. (A) Hepatic mRNA
expression levels of Pparα, Cyp4a14, Vnn1, Cyp4a10, Fsp27 and Tnfα were quantiﬁed by qRT-PCR. (B) Plasma glucose and free fatty acids (FFA)
were measured. (C and D) WT and PPARα hepatocyte-speciﬁc knockout (Pparαhep−/−) mice were treated with the β3-adrenergic receptor agonist
CL316243 at ZT6 and then killed at ZT14. (C) Quantiﬁcation of plasma FFA. (D) Relative mRNA expression levels of Fgf21, Cyp4a14, Vnn1, Cyp4a10
and Fsp27 were measured by qRT-PCR. Data are shown as mean±SEM. *p≤0.05, **p≤0.01, ***p≤0.005.
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linolenic acids in the liver during fasting (see online supplemen-
tary ﬁle 4), which is in agreement with the fact that both of
them are the main fatty acids stored in the white adipose tissues
of mice fed a chow diet.36 Importantly, we found a high correl-
ation between the kinetics of circulating FFA increase and
expression of PPARα and several of its target genes. Moreover,
treatment with a β3-adrenergic receptor agonist further
enhanced this response in vivo through PPARα but did not
induce detrimental FFA-sensitive response driven by toll-like
receptor 4 (TLR4). This is likely due to the mixture of FFA
released from the adipose stores. Indeed, fatty acids that accu-
mulated in the liver of Pparαhep−/− mice during fasting were
mostly oleic (C18:1n–9) and linoleic acids (C18:2n–6), and not
only saturated fatty acids such as palmitic acid (C16:0).
Interestingly, it has been shown that palmitic acid cannot acti-
vate TLR4 in the presence of unsaturated FFA.37
Overall, our data highlight hepatic PPARα activity regulation
by fatty acids released from adipocytes. This contrasts with the
previous evidence that PPARβ/δ rather than PPARα may act as a
FFA sensor.38 However, our data support the possibility that
this adipose-derived signal is time-restricted and speciﬁcally efﬁ-
cient in early night. Moreover, other pathways likely inﬂuence
PPARα activity by providing ligands.34 35 39 40 Several insulin-
sensitive signalling mechanisms inﬂuence hepatic PPARα, and
adipocyte lipolysis is insulin sensitive.41 Thus, insulin may
coordinate hepatic PPARα, both through cell-autonomous
mechanisms and adipocyte lipolysis inducing interorgan com-
munication mediated by FFA release. Our ﬁndings also corres-
pond with the recent evidence that adipocyte lipolysis may
regulate hepatic Fgf21.42 Circulating FGF21 was strictly
dependent on hepatocytic PPARα activation during fasting.
Most circulating FGF21 is liver-derived43 and Pparα−/− mice
Figure 7 Liver peroxisome proliferator-activated receptor α (PPARα) deﬁciency aggravates non-alcoholic steatohepatitis in response to a
methionine-deﬁcient and choline-deﬁcient diet (MCD). Wild-type (WT), PPARα hepatocyte knockout (Pparαhep−/−) and PPARα knockout (Pparα−/−)
mice were fed a MCD or a control diet for 2 weeks and were killed at ZT8. (A) Body weight gain was measured over 2 weeks. (B) Representative
pictures of H&E staining on liver sections. Scale bar, 100 mm. (C) Quantiﬁcation of hepatic triglycerides and cholesterol esters. (D) Alanine
transaminase activity level in plasma. (E) Hepatic mRNA expression levels of Cyp4a14, Vnn1 and Fgf21. (F) Plasma levels of ﬁbroblast growth factor
21 (FGF21). Data are shown as mean±SEM. *p≤0.05, **p≤0.01, ***p≤0.005.
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show very little FGF21.11 12 Other transcription factors can also
regulate hepatic Fgf21 expression44–48 and PPARα is also
expressed in extrahepatic tissues.13 Our ﬁndings in Pparαhep−/−
mice showed very little FGF21 without hepatic PPARα in both
fed and fasted states. Pparα−/− mice are hypoglycaemic and
hypothermic during fasting7 and FGF21 is known for its endo-
crine effect on glucose homeostasis and thermogenesis.13
However, compared with fasted Pparα−/− mice, fasted
Pparαhep−/− mice showed reduced hypoglycaemia and hypo-
thermia while FGF21 was equally absent in both models. This
indicates that extrahepatocytic PPARα strongly inﬂuenced
whole-body glucose homeostasis and temperature independ-
ently of hepatocyte PPARα and FGF21 production during
fasting. In addition, while FGF21 prevents steatosis in differ-
ent mouse models13 30 and FGF21 reduces hepatic lipids in
WT mice, its overexpression is not sufﬁcient to protect from
lipid accumulation in Pparαhep−/− and in Pparα−/− mice.
Therefore, the absence of FGF21 is not the primary cause for
the steatosis observed in Pparαhep−/− mice.
Lack of hepatic PPARα impairs the liver’s ability to use FFA
from acute lipolysis, resulting in steatosis. MCD diet-induced
weight loss49 50 also correlated with hepatic PPARα activity, sug-
gesting that chronic lipolysis elevates hepatocytic PPARα activity
in non-fasted mice. In agreement with the ﬁndings in whole-
body PPARα-deﬁcient mice,20 our data demonstrated that the
absence of hepatocytic PPARα was sufﬁcient to increase MCD
diet-induced liver damage. FGF21 expression/circulating levels
increased in steatohepatitis, supporting the possibility that ele-
vated FGF21 may reﬂect liver stress without fasting. This MCD
diet-induced FGF21 increase was not strictly PPARα-dependent,
consistent with the ﬁndings that amino acid deprivation induces
hepatic FGF21 expression through ATF4.44 PPARα presence led
to greater FGF21 increase, and may contribute to hepatoprotec-
tion from lipotoxic lipid accumulation.30
MCD diet is widely used for preclinical NASH studies.
However, it has many limitations, including the important
weight loss that occurs in mice fed such diet. Therefore, we also
tested the role of hepatocyte PPARα in lipid homeostasis in
response to a short-term HFD feeding, which is sufﬁcient to ini-
tiate early neutral lipid accumulation that may promote
NAFLD. Pparαhep−/− mice showed marked increase in hepatic
steatosis in response to 2 weeks of HFD feeding (see online sup-
plementary ﬁle 11) suggesting that hepatocyte PPARα plays a
dual role in exogenous (dietary) as well as in endogenous
(released from adipocyte lipolysis) fatty acid homeostasis.
Previous studies have shown that Pparα−/− mice show a sig-
niﬁcant alteration of systemic lipid metabolism that leads to
hepatic steatosis in ageing mice. Since PPARα is active in skeletal
muscles,23 adipose tissues,24 25 intestines,26 kidneys27 and
heart,28 which all contribute to fatty acid homeostasis, it is
impossible to determine whether the spontaneous steatosis that
occurs in ageing Pparα−/− mice originates from a defect in the
hepatocytic PPARα activity. This led us to investigate
ageing-related differences between Pparα−/− and Pparαhep−/−
Figure 8 Mice deﬁcient in hepatic peroxisome proliferator-activated receptor α (PPARα) develop spontaneous hepatic steatosis during ageing.
Wild-type (WT), PPARα hepatocyte knockout (Pparαhep−/−) and PPARα knockout (Pparα−/−) mice were fed a chow diet for 51 weeks. All mice were
killed at ZT16 in a non-fasted state. (A) Body weight gain was followed over time. (B) Comparison of body weight between weeks 11 and 50. (C)
Representative pictures of 52-week-old mice of the three genotypes. (D) Representative images of H&E staining of liver sections. Scale bar, 100 mm.
(E) Quantiﬁcation of hepatic triglycerides and cholesterol esters. (F) Measurement of plasma total cholesterol, HDL cholesterol and LDL cholesterol.
(G) Fasting glycaemia. Data are shown as mean±SEM. *p≤0.05, **p≤0.01, ***p≤0.005.
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mice. During ageing, Pparα−/− mice became overweight and
developed steatosis, while Pparαhep−/− mice only suffered stea-
tosis. Therefore, neither obesity nor hyperglycaemia, which are
both known to promote NAFLD,15 16 is responsible for the
steatosis observed in mice with hepatocyte-speciﬁc PPARα
deletion.
Furthermore, both Pparα−/− and Pparαhep−/− ageing mice were
hypercholesterolaemic. This is likely due to the dysregulation of
apolipoproteins gene expression as well as cholesterol transport
(Abcg8) as revealed in microarray analysis (see online supple-
mentary ﬁle 12A). It is also possible that the cholesterol biosyn-
thesis pathway driven by SREBP-2 may be dysregulated in the
absence of PPARα since some of the SREBP-2 genes are elevated
in Pparα−/− and/or in Pparαhep−/− mice (see online supplemen-
tary ﬁle 12B). Therefore, this suggests that drugs that activate
hepatocytic PPARα will likely inﬂuence whole-body fatty acid
and cholesterol homeostasis.
Altogether, our extensive analysis performed in Pparαhep−/−
mice has allowed us to extend the evidence for the central role
of PPARα in hepatocyte fatty acid homeostasis (ﬁgure 9).
PPARα is strikingly essential to many aspects of fatty acid
homeostasis including degradation through oxidative pathways.
Our work provides the ﬁrst demonstration that hepatocyte-
speciﬁc PPARα deletion impairs whole-body fatty acid homeo-
stasis during fasting, MCD and HFD feeding as well as in
ageing. These ﬁndings underscore the central role of PPARα in
the clearance of dietary fatty acids and of FFA released from
adipocytes, the major source of lipid accumulation in NAFLD.
These data highlight the relevance of PPARα as a drug target for
NAFLD treatment.
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Figure 9 Overview of
hepatocyte-speciﬁc peroxisome
proliferator-activated receptor α
(PPARα)-regulated genes involved in
fatty acid metabolism. This ﬁgure was
designed based on transcriptome
analysis of PPARα-dependent gene
expression in hepatocytes. Genes listed
in regular font are induced by
fenoﬁbrate and by fasting in wild-type
(WT) but not in Pparαhep−/− mice.
Genes in italics are repressed by
fenoﬁbrate and by fasting in WT but
not in Pparαhep−/− mice. Genes
referenced in bold are downregulated
in Pparαhep−/− compared with WT
mice, whatever the conditions.
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